Monthly archives for April, 2021
Latest Research Reports On Stocks By Leading Brokerages: If you have any research reports that you would like to share with us, please send it to michael@rakesh-jhunjhunwala.in or to admin@rakesh-jhunjhunwala.in. (The pre-June 2016 reports are available here).
| Covid 2.0: Investment Ideas | |
| Company: | Model Portfolio |
| Brokerage: | Axis Securities |
| Date of report: | April 23, 2021 |
| Type of Report: | Model Portfolio |
| Recommendation: | Buy |
| Upside Potential: | 39% |
| Summary: | Reduce NIFTY50 target to 16100 but remain cautiously optimistic |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | Axis Securities, Model Portfolio |
| IndiaMART InterMESH Research Report By HDFC Securities | |
| Company: | IndiaMART InterMESH |
| Brokerage: | HDFC Sec |
| Date of report: | April 13, 2021 |
| Type of Report: | Initiating Coverage |
| Recommendation: | Buy |
| Upside Potential: | 59% |
| Summary: | Stellar operating leverage |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | HDFC Sec, IndiaMART InterMESH |
| Best Cement Stocks To Buy Now: HDFC Sec Research Report | |
| Company: | HDFC Sec, Model Portfolio |
| Brokerage: | HDFC Sec |
| Date of report: | April 13, 2021 |
| Type of Report: | Sector Report |
| Recommendation: | Buy |
| Upside Potential: | 100% |
| Summary: | long-term trends are likely to drive the cement industry over the next few years |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | Best Cement stocks, Model Portfolio, Sagar Cement Ltd |
| Top 5 Pharma Stocks To Buy Now: Edelweiss Research Report | |
| Company: | Model Portfolio, Sun Pharma |
| Brokerage: | Edelweiss |
| Date of report: | April 12, 2021 |
| Type of Report: | Model Portfolio |
| Recommendation: | Buy |
| Upside Potential: | 22% |
| Summary: | SUN PHARMA entering into an earnings upgrade cycle |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | 5 Best Pharma Stocks, Edelweiss, Model Portfolio |
| Vinati Organics Ltd Research Report By Edelweiss | |
| Company: | Vinati Organics |
| Brokerage: | Edelweiss |
| Date of report: | April 9, 2021 |
| Type of Report: | Result Update |
| Recommendation: | Buy |
| Upside Potential: | 21% |
| Summary: | Refuelling for next leg of growth |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | Edelweiss, Vinati Organics |
| Innerwear Industry – Sector Report By SMIFS | |
| Company: | Dollar Industries, Lux Industries, Page Industries, Rupa & Co |
| Brokerage: | Stewart & Mackertich |
| Date of report: | April 6, 2021 |
| Type of Report: | Sector Report |
| Recommendation: | Buy |
| Upside Potential: | 100% |
| Summary: | The Indian innerwear market was valued at ~Rs 320 billion in 2018 and is expected to grow at a CAGR of ~11% over the next decade to reach ~Rs 897 billion by 2028E |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | innerwear industry, SMIFS |
| Axis Top Picks for April 2021 | |
| Company: | Model Portfolio |
| Brokerage: | Axis Securities |
| Date of report: | April 1, 2021 |
| Type of Report: | Model Portfolio |
| Recommendation: | Buy |
| Upside Potential: | 100% |
| Summary: | New Fiscal; New Hope! |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | Axis Securities, Model Portfolio |
| CONCOR Initiating Coverage Research Report By Nirmal Bang | |
| Company: | CONCOR |
| Brokerage: | Nirmal Bang |
| Date of report: | March 31, 2021 |
| Type of Report: | Initiating Coverage |
| Recommendation: | Buy |
| Upside Potential: | 18% |
| Summary: | Best is yet to come! |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | Concor, Nirmal Bang |
| Best 5 Specialty Ingredients Stocks To Buy Now: Research Report By Nirmal Bang | |
| Company: | Advanced Enzymes Technologies, Camlin Fine Sciences, Fine Organic, Galaxy Surfactants, Model Portfolio, Rossari Biotech |
| Brokerage: | Nirmal Bang |
| Date of report: | April 1, 2021 |
| Type of Report: | Initiating Coverage |
| Recommendation: | Buy |
| Upside Potential: | 29% |
| Summary: | Indian companies are leveraging this opportunity whereby they deal with some global companies for sourcing ingredients and subsequently provide value-added solutions to clients based on their requirements |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | Model Portfolio, Nirmal Bang, Speciality Chemicals |